Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Mild to Moderate Psoriatic Fingernail/s

Inclusion Criteria: * Written informed consent before starting any study related procedure. * Patients ages ≥ 18 and ≤ 80 years old. * Men or women. * Outpatients. * Patients with mild to moderate psoriatic fingernail/s, defined as fingernail/s with matrix psoriasis NAPSI score and/or bed psoriasis NAPSI score ≥ 1 and ≤ 3 at baseline. The sum of the scores for each nail should range between 1 and 6. * In case of skin involvement, patients with established clinical diagnosis of mild to moderate psoriasis (BSA involvement ≤ 8% or Psoriasis Area Severity Index (PASI) ≤ 10). Exclusion Criteria: * Use of any systemic treatment for psoriasis and/or nail psoriasis during the last six months before the screening visit. * Use of any topical treatment for nail psoriasis on fingernails during the last six months before the screening visit. * Use of photochemotherapy (phototherapy is allowed) or other forms of radiotherapy during the last four weeks before the screening visit. * Positive mycology findings (KOH evaluation or culture) obtained in the three months before the screening visit or positive KOH evaluated at the screening visit. * Patients using nail polish or other nail cosmetic products during last 72 hours prior to study drug application. * Systemic use of the following therapies for any reason during last three months before the screening visit: immunosuppressives, chemotherapy and corticosteroids (topical use for plaque psoriasis is allowed). * Consumption of oral Vitamin…